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symptomatic pseudo-progression after SRT of brain 
metastases needs to be considered as a serious radiation 
induced toxicity. Reduction of the high dose volume of 
normal brain tissue may prevent this toxicity. 
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Purpose or Objective: Following EBRT for prostate cancer, 
patients can develop aggravation of urinary symptoms mostly 
due to urethral dose. With dose-escalated EBRT it is 
suggested that genitourinary toxicity increases with 
increasing dose. In the experimental arm of the FLAME-trial 
(284 patients) a dose of 77Gy to the entire prostate gland in 
35 fractions was administered, with an integrated boost up to 
95Gy to the macroscopic lesions. No dose constraints for the 
urethra were set during the trial. The objective of this study 
is to evaluate urethral dose parameters, urethra-related 
toxicity and prostate-specific QoL scores for patients treated 
with and without dose-escalated EBRT.  
 
Material and Methods: Between 2009 and 2015, 571 
intermediate and high risk prostate cancer patients were 
enrolled in the FLAME trial, a phase 3, single blind, multi-
center randomized controlled trial (NCT01168479). The 
control arm (287 patients) received a dose of 77Gy to the 
entire prostate gland in 35 fractions. The experimental arm 
(284 patients) received the same dose, but with an 
integrated boost up to 95Gy to the multi-parametric MRI-
based intraprostatic lesion. For this study, the urethra was 
delineated retrospectively on T2 weighted MRI, using a circle 
shape with a diameter of 3 mm, to obtain dose parameters. 
These dose parameters, the Genitourinary Toxicity 
scores(CTCAE v3.0) and the urinary symptoms scale of the 
EORTC QLQ-PR25, were compared for both treatment arms. 
The physician in attendance scored toxicity at baseline, 
weekly during treatment, 4 weeks after treatment and every 
6 months up to 10 years. QoL was filled out 1 week before 
treatment and the next questionnaires were sent to the 
patient every 6 months up to 10 years. Mean differences 
between groups at 1 year of follow-up were calculated using 
an independent samples t-test (dosimetry and QoL), Chi-
square test or Fisher’s exact test (toxicity). Statistical 
significance was considered P<0.01.  
 
Results: Results after analysis of 100 patients (50 patients in 
each treatment arm) with a median follow-up of 22 months 
show for the control arm an average Dmean (mean dose to 
the urethra) of 77.3 ± 0.5 Gy (range 75.9-78.0 Gy), with an 
average Dmax (maximum dose to the urethra) of 79.6 ± 0.8 
Gy (range 78.0-81.3). In the experimental arm, average 
Dmean was 82.0 ± 2.8 Gy (range 77.4-89.0 Gy) and average 
Dmax was 89.7 ± 0.6 Gy (range 80.7-97.7 Gy). For both 
Dmean and Dmax the difference between treatment arms 
was significant (p=0.000). Grade 3 GU toxicity did not occur, 
grade 2 GU toxicity occurred in a subset of patients, although 
no significant difference was found between both treatment 
arms for the separate GU items (table 1). Urinary symptoms-
related QOL was not significantly different across treatment 
arms. 
 
 
Conclusion: Results showed a significant difference in 
urethral dose, but no significant differences in toxicity or 
quality of life when comparing both treatment arms of the 
FLAME trial. 
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Purpose or Objective: Radiotherapy of lung cancer delivers 
quite high doses of radiation to the heart. We explored 
associations between overall survival (OS) and radiation dose 
to heart and its substructures and electrocardiographic (ECG) 
changes. 
 
Material and Methods: We analysed data from 79 patients in 
IDEAL CRT, a phase I/II trial of isotoxic radiotherapy (RT) 
dose escalation trial, sponsored by University College London 
(C13530/A10424). Mean and maximum prescribed doses were 
69 and 75.6Gy calculated as 2Gy fractionation equivalents 
(EQD2, α/β=10Gy). Whole heart, left ventricle (LV), right 
ventricle (RV), right atrium (RA), left atrium (LA) and AV 
node (AVN) were outlined on RT planning scans and 
differential dose volume histograms (DVHs) extracted, 
converting physical DVHs to EQD2s (α/β=3). Patient-to-
patient DVH variability was represented using a small number 
of Varimax-rotated principal components (PCs) explaining 
95% of total variance. ECGs were analysed at baseline, 6 and 
12 months (mo) after treatment, and changes in heart rate 
(HR) recorded, with patients dichotomised according to 
presence or absence of ‘any ECG rhythm change’ (conduction 
abnormalities or ischaemia). OS was modelled using Cox 
regression from the start of treatment. Univariate analysis 
(UVA) and multivariate analysis (MVA) of clinical factors 
included ‘any rhythm ECG change’ at 6 and 12 months, 
change in HR at 6 or 12 months, planning target volume 
(PTV), and prescribed dose (PD). MVA of whole heart 
dosimetric factors included all 7 Heart PCs, PTV, and PD. MVA 
of heart substructures included heart substructure PCs with p 
< 0.2 on UVA having similar dosimetric distributions to 
significant Heart PCs, PTV and PD. 
 
